Abiopharma

🔍 Porshnev Peter (Executive)

Company: VEECO INSTRUMENTS INC (VECO)

Report Date: 2026-03-20

Detailed Transactions and Holdings:

• Acquired 26,910 shares of Common Stock (Direct)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 205,863.31 | transaction_form_type: 4 | Footnotes: F1
• Sold 11,397 shares of Common Stock at $31.0 per share (Direct)
  Date: 2026-03-20 | Code: F | equity_swap_involved: 0 | shares_owned_after: 194,466.31 | transaction_form_type: 4 | Footnotes: F2
• Acquired 593 shares of Common Stock at $25.959 per share (Direct)
  Date: 2026-03-20 | Code: A | equity_swap_involved: 0 | shares_owned_after: 195,059.31 | transaction_form_type: 5 | Footnotes: F3

Footnotes:

• F1: On March 13, 2023, the reporting person was granted the contingent right to receive 15,600 performance-based restricted stock units ("PRSUs"). This contingent right was subject to the reporting person's continued service with the Company and the achievement of three-year performance criteria, which was based on the Company's total shareholder return relative to other companies in the Russell 2000 as specified in the award agreement (the "Criteria"). Each PRSU represented the contingent right to receive one share of Veeco common stock. The award, if earned, could range from 50% to 200% of the granted PRSUs based on the achievement of the Criteria. The common stock award reflected in this filing represents achievement at the 172.5% level, which was realized.
• F2: Represents securities surrendered to Veeco to satisfy tax withholding obligations due upon the vesting of restricted stock.
• F3: Represents 593 shares purchased under the Veeco Employee Stock Purchase Plan on March 20, 2026.